Virpax Pharmaceuticals Enters Into Cooperative Research And Development Agreement With The National Advisory Neurological Disorders And Stroke Council
Portfolio Pulse from Happy Mohamed
Virpax Pharmaceuticals (NASDAQ: VRPX) has entered into a cooperative research and development agreement with the National Institute of Neurological Disorders and Stroke (NINDS). The partnership will focus on evaluating Virpax's NobrXiol product candidate for the management of rare pediatric epilepsy using a unique intranasal Molecular Envelope Technology (MET) delivery platform.
June 21, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Virpax Pharmaceuticals partners with NINDS to evaluate its NobrXiol product for rare pediatric epilepsy management, potentially leading to higher bioavailability and reduced side effects.
The partnership with NINDS is significant for Virpax Pharmaceuticals as it could lead to the development of a more effective treatment for rare pediatric epilepsy. The use of the unique intranasal MET delivery platform may result in higher bioavailability, faster onset, and reduced side effects, potentially making NobrXiol a competitive product in the market. This collaboration is likely to have a positive short-term impact on Virpax's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100